425: Strive CEO Comments on Semler Scientific Merger

Strive CEO Matthew Cole posted on X.com regarding the proposed business combination with Semler Scientific, Inc., prompting an SEC filing.

Summary

• The filing is a communication posted by Strive CEO Matthew Cole on X.com on September 22, 2025, concerning Strive's proposed business combination with Semler Scientific, Inc.
• It includes a cautionary statement regarding forward-looking statements related to the proposed transaction, outlining inherent risks and uncertainties.
• The document advises investors and stockholders to read the Registration Statement on Form S-4, which will include an Information Statement/Proxy Statement/Prospectus, for important information about the transaction.
• It identifies Strive, Semler Scientific, and certain directors, executive officers, and employees as potential participants in the solicitation of proxies for the proposed transaction.
• The communication clarifies that it does not constitute an offer to sell or a solicitation of an offer to buy securities or a solicitation of any vote of approval.

Sentiment

Score: 5

Explanation: The filing is a standard cautionary statement regarding a proposed business combination. While the underlying event (merger) is significant, the document itself is neutral in tone, focusing heavily on outlining numerous risks and forward-looking uncertainties, which balances any implied positivity of the merger announcement.

Positives

• The proposed transaction is anticipated to yield strategic benefits and financial benefits for the combined company.
• Expected impacts include anticipated cost savings and strategic gains.

Negatives

• The proposed transaction may not close when expected or at all due to unmet conditions.
• Anticipated benefits, including cost savings and strategic gains, may not be realized.
• Integration of the two companies could be more difficult, time-consuming, or costly than expected.
• The transaction may be more expensive or take longer to complete than anticipated.
• Management's attention may be diverted from ongoing business operations and opportunities.
• Shareholders may experience dilution due to Strive's issuance of additional Class A common stock in connection with the transaction.
• There is a risk of potential adverse reactions from Strive's or Semler Scientific's customers or changes to business or employee relationships.
• Changes in Strive's or Semler Scientific's share price could occur before closing.

Risks

• The occurrence of any event, change, or circumstances that could give rise to the right of one or both companies to terminate the merger agreement.
• The possibility that the proposed transaction does not close when expected or at all because conditions to closing are not received or satisfied on a timely basis or at all.
• The outcome of any legal proceedings that may be instituted against Strive, Semler Scientific, or the combined company.
• The possibility that anticipated benefits of the proposed transaction, including cost savings and strategic gains, are not realized when expected or at all.
• Risks associated with changes in, or problems arising from, implementation of Bitcoin treasury strategies and risks associated with Bitcoin and other digital assets.
• General economic and market conditions, interest and exchange rates, monetary policy, and laws and regulations and their enforcement.
• The possibility that the integration of the two companies may be more difficult, time-consuming, or costly than expected.
• The possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events.
• The diversion of management's attention from ongoing business operations and opportunities.
• Dilution caused by Strive's issuance of additional shares of its Class A common stock in connection with the proposed transaction.
• Potential adverse reactions of Strive's or Semler Scientific's customers or changes to business or employee relationships, including those resulting from the announcement or completion of the proposed transaction.
• Changes in Strive's or Semler Scientific's share price before closing.
• Other factors that may affect future results of Strive, Semler Scientific, or the combined company, including unknown or unpredictable factors.

Future Outlook

The outlook and expectations of Strive and Semler Scientific regarding the proposed transaction include anticipated strategic and financial benefits, expected impact on the combined company's future financial performance, and the timing of the closing and successful integration of the businesses. These are subject to significant risks and uncertainties.

Industry Context

This filing is a standard regulatory disclosure related to a specific corporate merger event and does not provide broader industry trend analysis or context.

Legal Proceedings

• The outcome of any legal proceedings that may be instituted against Strive or Semler Scientific or the combined company is identified as a risk factor for the proposed transaction.

Related Party Transactions

• Information regarding Semler Scientific's transactions with related persons is set forth in its definitive proxy statement in connection with its 2025 Annual Meeting of Stockholders.

Stakeholder Impact

• Shareholders of Strive will experience dilution due to the issuance of additional Class A common stock in connection with the proposed transaction.
• There is a risk of potential adverse reactions from Strive's or Semler Scientific's customers.
• Changes to business or employee relationships are a potential risk resulting from the announcement or completion of the proposed transaction.

Next Steps

• Strive intends to file a Registration Statement on Form S-4 with the SEC to register Class A common stock to be issued in connection with the proposed transaction.
• The Registration Statement will include an Information Statement of Strive, a proxy statement of Semler Scientific, and a prospectus of Strive.
• A definitive Information Statement/Proxy Statement/Prospectus will be sent to Semler Scientific stockholders to seek their approval of the proposed transaction.

Key Dates

Keywords

Strive Inc., Semler Scientific Inc., Merger, Business Combination, SEC Filing, Form 425, Forward-Looking Statements, Acquisition, Corporate Governance, Risk Management